>
Health Illuminated

Producing
Medical Isotopes

In Phase 2, we are combatting chronic shortages of critical nuclear medicine, domestically and across the globe. These shortages directly impact patient diagnoses and treatment of heart disease, cancer, and other serious illnesses. We plan to use the neutrons produced by fusion as a driver to produce both therapeutic and diagnostic medical isotopes.

IMPROVING PATIENT OUTCOMES

Lutetium-177 for Precision Cancer Treatment

In targeted cancer therapy, our cancer-fighting medical isotope, lutetium-177, is paired with cancer-seeking medicine. They form a smart compound that directly targets and attacks specific cells, leaving surrounding tissue relatively untouched. We are rapidly scaling our production of Lu-177 to meet the demand created by exciting new therapies. Our goal is to become the first vertically integrated manufacturer of Lu-177 in the world.

Medical screen chartMedical screen chartAn internal view of the human body showing metastatic cancer
A young woman embraces an elderly woman receiving medical treatment
DETECTING LIFE-THREATENING CONDITIONS

Molybdenum-99 Powers Diagnostic Medical Imaging

Early detection of heart disease, cancer and many other diseases is critical when it comes to providing patients with enhanced treatment options, planning flexibility, lower-cost interventions and more.
Molybdenum-99 is the hardest-working diagnostic medical isotope in the world, powering approximately 40 million patient scans each year, with roughly 50% of those in North America. We have plans to satisfy more than half the world’s demand through the company’s mass production facility, The Chrysalis, which is currently under construction in Janesville, Wisconsin.

WHY ISOTOPES MADE WITH SHINE?

Safe, U.S.-Based Access to Critical Medicine

Today, most medical isotopes are produced in six research reactors, none of which are in North America. The short half-lives of these isotopes mean a significant amount of the product is lost due to decay during overseas shipping. Our technology is designed to produce isotopes without research reactors or highly enriched uranium. We intend to bolster supply chain efficiency and bring medical isotope production technology back to the U.S., where it was first invented and commercialized.

A scientist wearing PPE using a micropipetteCancer therapy medication in SHINE packaging

What We've Achieved

We've designed our four-phased approach to produce meaningful outcomes at each stage as we work toward fusion energy.
We're proud to have accomplished key milestones during Phase 2: Producing Medical Isotopes.

2015
SHINE’s molybdenum-99 sample demonstrates equivalence to reactor-based production
2016
Nuclear Regulatory Commission issues construction permit for The Chrysalis
2019
WE BELIEVE WE SET A WORLD RECORD FOR A NUCLEAR FUSION REACTION IN A STEADY-STATE SYSTEM, YIELDING 46 TRILLION NEUTRONS PER SECOND
2022
Drug Master File for n.c.a. lutetium-177 submitted to U.S. Food and Drug Administration
2023
NRC issues Final Safety Evaluation Report for The Chrysalis
A blue neutron beam
A blue neutron beam
2015
SHINE’S MOLYBDENUM-99 SAMPLE DEMONSTRATES EQUIVALENCE TO REACTOR-BASED PRODUCTION
2016
NUCLEAR REGULATORY COMMISSION ISSUES CONSTRUCTION PERMIT FOR THE CHRYSALIS
2019
WE BELIEVE WE SET A WORLD RECORD FOR A NUCLEAR FUSION REACTION IN A STEADY-STATE SYSTEM, YIELDING 46 TRILLION NEUTRONS PER SECOND
2022
DRUG MASTER FILE FOR N.C.A. LUTETIUM-177 SUBMITTED TO U.S. FOOD AND DRUG ADMINISTRATION
2023
NRC ISSUES FINAL SAFETY EVALUATION REPORT FOR THE CHRYSALIS

Redefine What's Possible

We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.